Recent news
June 2011
WHO prequalifies typhoid vaccine
June 30, 2011 -- The pharmaceutical company Sanofi Pasteur recently announced that the World Health Organization (WHO) has granted pre-qualification to its typhoid vaccine, making Typhim Vi the first WHO pre-qualified vaccine for typhoid. Under the WHO’s prequalification program, the agency provides an independent opinion on the quality, safety, and efficacy of drugs and vaccines required for purchase by United Nations procurement agencies. Although WHO is not a regulator, its prequalification program is an important signal of quality, safety, and efficacy to countries without sufficient regulatory capabilities.
“In line with our ambition to provide the best vaccines at affordable prices to developing countries, Sanofi Pasteur is truly pleased and proud to bring to the immunization community the first WHO-pre-qualified typhoid vaccine, Typhim Vi, to help combat a serious disease that affects the lives of millions of individuals each year particularly in the most impoverished countries,” said Olivier Charmeil, president and CEO of Sanofi Pasteur.
In related news, Sanofi Pasteur has opened a new $100 million dollar vaccine research and development facility in Toronto, Canada. The Toronto site manufactures many global health vaccines, with 94 percent of its vaccine production being delivered to more than 90 countries around the world. See the links below for more information.
